1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported): March 3, 1997
ImmuLogic Pharmaceutical Corporation
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware
- --------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
0-19117 13-339757
- ----------------------- -------------------
(Commission File Number (I.R.S. Employer
Identification No.)
610 Lincoln Street
Waltham, Massachusetts 02154
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(617) 466-6000
- --------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
Not Applicable
- --------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
2
Item 5. Other Events.
- ----------------------
On March 5, 1997, The Company announced a restructuring of its Board of
Directors. Five new members were appointed to the seven person Board of
Directors. They are J. Joseph Marr, M.D., acting President and Chief Executive
Officer of ImmuLogic; C. Garrison Fathman, M.D., Professor, Department of
Medicine and Immunology, Stanford University School of Medicine; Carl
Goldfischer, M.D., Chief Financial Officer, Vice President Finance and Strategic
Planning of ImClone Systems Incorporated; Geraldine Henwood, Chief Executive
Officer of IBAH, Inc.; and Richard Pops, Chief Executive Officer of Alkermes
Inc. These appointments followed the resignations of Malcolm Gefter, Ph.D.,
Chairman of the Board and scientific founder, Alan Dalby, Howard Jacobson,
Kenneth Melmon, M.D., and Larry Soll, Ph.D. Samuel Fleming, Chairman and Chief
Executive Officer of Decision Resources, Inc. and Paul Friedman, M.D., President
of Dupont Merck Research Labs, each of whom was appointed to the Board of
Directors in September 1996, will continue to serve as Directors.
The Company has entered into a severance agreement with Dr. Gefter
providing for payments to Dr. Gefter commensurate with those otherwise due under
his employment contract.
Item 7. Financial Statements and Exhibits
- ------------------------------------------
Exhibit
No. Description
--- -----------
99.1 Press Release dated March 5, 1997.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: March 13, 1997 IMMULOGIC PHARMACEUTICAL
CORPORATION
/S/ John Morrison
------------------------------------
By: John Morrison
Title: Acting Chief Financial Officer
4
Exhibit Index
-------------
Exhibit No. Exhibit
- ----------- -------
99.1 Press Release, dated March 5, 1997